

- of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes. *Oncology* 66 (2004): 323-330.
42. Ilan Y, Margalit M, Ohana M, et al. Alleviation of chronic GVHD in mice by oral immunoregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect. *Hum Immunol* 66 (2005): 231-340.
 43. Elinav E, Pappo O, Sklair-Levy M, et al. Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. *J Pathol* 208 (2006): 74-81.
 44. Ilan Y. Oral tolerance: can we make it work? *Hum Immunol* 70 (2009): 768-776.
 45. Ilan Y, Zigmund E, Lalazar G, et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. *J Clin Immunol* 30 (2010): 167-177.
 46. Ilan Y, Ben Ya'acov A, Shabbat Y, et al. Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis. *World J Gastroenterol* 22 (2016): 8760-8769.
 47. Safadi R, Israeli E, Papo O, et al. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. *Am J Gastroenterol* 98 (2003): 2505-2515.
 48. Israeli E, Safadi R, Melhem A, et al. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial. *Liver Int* 24 (2004): 295-307.
 49. Israeli E, Goldin E, Shibolet O, et al. Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial. *World J Gastroenterol* 11 (2005): 3105-3111.
 50. Margalit M, Israeli E, Shibolet O, et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. *Am J Gastroenterol* 101 (2006): 561-568.
 51. Israeli E, Ilan Y. Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease. *Therap Adv Gastroenterol* 3 (2010): 23-30.
 52. Mizrahi M, Shabat Y, Ben Ya'acov A, et al. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. *J Inflamm Res* 5 (2012): 141-150.
 53. Israeli E, Goldin E, Fishman S, et al. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. *Clin Exp Immunol* 181 (2015): 362-372.
 54. Israeli E, Zigmund E, Lalazar G, et al. Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial. *World J Gastroenterol* 21 (2015): 5685-5694.
 55. Lalazar G, Mizrahi M, Turgeman I, et al. Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. *J Clin Immunol* 35 (2015): 399-407.
 56. Ilan Y. Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease. *Clin Transl Immunology* 5 (2016): e60.
 57. Almon E, Khoury T, Drori A, et al. An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. *J Immunol Methods* 446 (2017): 21-29.
 58. Lalazar G, Zigmund E, Weksler-Zangen S, et al. Oral Administration of beta-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. *J Med Food* 20 (2017): 458-464.
 59. Ilan Y, Shailubhai K, Sanyal A. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH. *Clin Exp Immunol* 193 (2018): 275-283.
 60. Ishay Y, Potruch A, Weksler-Zangen S, et al. Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19. *Drug Dev Res* (2021).
 61. Ilan Y. Overcoming randomness does not rule out the importance of inherent randomness for functionality. *J Biosci* 44 (2019).
 62. Ilan Y. Generating randomness: making the most out of disordering a false order into a real one. *J Transl Med* 17 (2019): 49.

63. Ilan Y. Advanced Tailored Randomness: A Novel Approach for Improving the Efficacy of Biological Systems. *J Comput Biol* 27 (2020): 20-29.
64. Ilan Y. Order through Disorder: The Characteristic Variability of Systems. *Front Cell Dev Biol* 8 (2020): 186.
65. Li G, Obeng E, Shu J, et al. Genomic Variability and Post-translational Protein Processing Enhance the Immune Evasion of *Mycoplasma hyopneumoniae* and Its Interaction With the Porcine Immune System. *Front Immunol* 11 (2020): 510943.
66. Khoury T, Ilan Y. Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies. *Front Immunol* 10 (2019): 2726.
67. Lindenau JD, Salzano FM, Hurtado AM, et al. Variability of innate immune system genes in Native American populations-relationship with history and epidemiology. *Am J Phys Anthropol* 159 (2016): 722-728.
68. Shen-Orr SS, Furman D. Variability in the immune system: of vaccine responses and immune states. *Curr Opin Immunol* 25 (2013): 542-547.
69. Lévi F. [Chronopharmacology and chronotherapy of cancers]. *Pathol Biol* 565 (Paris) 44 (1996): 631-644.
70. Kessler A, Weksler-Zangen S, Ilan Y. Role of the Immune System and the Circadian Rhythm in the Pathogenesis of Chronic Pancreatitis: Establishing a Personalized Signature for Improving the Effect of Immunotherapies for Chronic Pancreatitis. *Pancreas* 49 (2020): 1024-1032.
71. Ishay Y, Kolben Y, Kessler A, et al. Role of circadian rhythm and autonomic nervous system in liver function: a hypothetical basis for improving the management of hepatic encephalopathy. *Am J Physiol Gastrointest Liver Physiol* 321 (2021): G400-G412.
72. Kolben Y, Weksler-Zangen S, Ilan Y. Adropin as a potential mediator of the metabolic system-autonomic nervous system-chronobiology axis: Implementing a personalized signature-based platform for chronotherapy. *Obes Rev* 22 (2021): e13108.
73. Kenig A, Kolben Y, Asleh R, et al. Improving Diuretic Response in Heart Failure by Implementing a Patient-Tailored Variability and Chronotherapy-Guided Algorithm. *Front Cardiovasc Med* 8 (2021): 695547.
74. Azmanov H, Ross EL, Ilan Y. Establishment of an Individualized Chronotherapy, Autonomic Nervous System, and Variability-Based Dynamic Platform for Overcoming the Loss of Response to Analgesics. *Pain Physician* 24 (2021): 243-252.
75. Potruch A, Khoury ST, Ilan Y. The role of chronobiology in drug-resistance epilepsy: The potential use of a variability and chronotherapy-based individualized platform for improving the response to anti-seizure drugs. *Seizure* 80 (2020): 201-211.
76. Isahy Y, Ilan Y. Improving the long-term response to antidepressants by establishing an individualized platform based on variability and chronotherapy. *Int J Clin Pharmacol Ther* 59 (2021): 768-774.
77. Khoury T, Ilan Y. Platform introducing individually tailored variability in nerve stimulations and dietary regimen to prevent weight regain following weight loss in patients with obesity. *Obes Res Clin Pract* 15 (2021): 114-123.
78. Kenig A, Ilan Y. A Personalized Signature and Chronotherapy-Based Platform for Improving the Efficacy of Sepsis Treatment. *Front Physiol* 10 (2019): 1542.
79. Ilan Y. Why targeting the microbiome is not so successful: can randomness overcome the adaptation that occurs following gut manipulation? *Clin Exp Gastroenterol* 12 (2019): 209-217.
80. Ilan Y. beta-Glycosphingolipids as Mediators of Both Inflammation and Immune Tolerance: A Manifestation of Randomness in Biological Systems. *Front Immunol* 10 (2019): 1143.
81. Gelman R, Bayatra A, Kessler A, et al. Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. *Emerg Microbes Infect* 9 (2020): 1397-1406.
82. Ishay Y, Potruch A, Schwartz A, et al. A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage. *Biomed Pharmacother* 143 (2021): 112228.
83. Ilan Y, Spigelman Z. Establishing patient-tailored variability-based paradigms for anti-cancer therapy: Using the inherent trajectories which underlie cancer for overcoming drug resistance. *Cancer Treat Res Commun* 25 (2020): 100240.
84. Hurvitz N, Azmanov H, Kesler A, et al. Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases. *Eur J Hum Genet* 29 (2021): 1485-1490.
85. Ilan Y. Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response. *Front Med (Lausanne)* 8 (2021): 788777.

86. Gelman R, Berg M, Ilan Y. A Subject-Tailored Variability-Based Platform for Overcoming the Plateau Effect in Sports Training: A Narrative Review. *Int J Environ Res Public Health* 19 (2022).
87. Azmanov H, Bayatra A, Ilan Y. Digital Analgesic Comprising a Second-Generation Digital Health System: Increasing Effectiveness by Optimizing the Dosing and Minimizing Side Effects. *J Pain Res* 15 (2022): 1051-1060.